Tissue Regenix Group PLC Notice of Results
01 Marzo 2024 - 8:00AM
RNS Regulatory News
RNS Number : 9779E
Tissue Regenix Group PLC
01 March 2024
Tissue Regenix Group
plc
('Tissue Regenix', the 'Group', or the
'Company')
Notice of full year
results
Investor
presentation
Tissue Regenix Group plc (AIM: TRX),
the regenerative medical devices company, will announce its
final results for the year ended 31 December 2023
on Tuesday 19 March 2024.
Investor Briefing
Daniel Lee, Chief Executive Officer,
and David Cocke, Chief Financial Officer, will host a live online
presentation relating to the final results via the Investor Meet
Company platform at 11.00am on Tuesday 19
March 2024. The presentation is open to all existing and potential
shareholders.
Investors can sign up to Investor
Meet Company for free and register for the presentation here:
https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
Investors who already follow Tissue
Regenix on the Investor Meet Company platform will be de facto
invited.
For more
information:
Tissue Regenix
Group plc
|
www.tissueregenix.com
|
David Cocke, Chief Financial Officer
|
via Walbrook
PR
|
|
|
Cavendish
Capital Markets Limited (Nominated Adviser and
Broker)
|
|
Emily Watts/Geoff Nash/George Dollemore -
Corporate Finance
|
|
Nigel Birks/Harriet Ward - ECM
|
|
|
|
Walbrook PR (Financial PR and IR)
|
Tel: +44
(0)20 7933 8780
|
Alice Woodings/Charlotte Edgar
|
TissueRegenix@walbrookpr.com
|
|
| |
About Tissue Regenix
(www.tissueregenix.com)
Tissue Regenix is a leading medical device
company in regenerative medicine. The Company's patented
decellularisation technology (dCELL®) removes DNA and other
cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that
can be used to repair diseased or damaged body structures. Current
applications address many crucial clinical needs in sports
medicine, foot and ankle injuries, and wound care.
In August 2017, Tissue
Regenix acquired CellRight Technologies®. This biotech company
specialises in regenerative medicine and is dedicated to developing
high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's
human tissue products may be used in spine, trauma, general
orthopaedic, dental and ophthalmological surgical
procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORDZGZZGLRGDZM
Grafico Azioni Tissue Regenix (LSE:TRX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Tissue Regenix (LSE:TRX)
Storico
Da Mag 2023 a Mag 2024